A recent review highlights the critical role of glutathione S-transferases (GSTs) in human health, emphasizing their influence on disease development, drug metabolism, and therapeutic interventions. These enzymes are responsible for detoxifying harmful compounds, but their dysregulation is linked to severe conditions, including cancer, neurodegenerative disorders, and chronic inflammatory diseases. Genetic variations in GSTs can lead to oxidative stress, DNA damage, and resistance to apoptosis, making them key players in disease pathogenesis.

This new review article published in Genes & Diseases sheds light on the pivotal role of fatty acid oxidation (FAO) in the complex landscape of cancer metabolism. Traditionally overshadowed by the widely recognized Warburg effect, FAO is now emerging as a crucial metabolic pathway that fuels tumor development, influences drug resistance, and presents promising therapeutic targets.

Hepatocellular carcinoma (HCC), the most common form of liver cancer, continues to pose a significant global health challenge due to its high mortality rate and limited treatment options. However, a new frontier in cancer therapy has emerged, focusing on neddylation modification, a crucial cellular process that influences cancer progression. The latest insights into this mechanism provide hope for targeted therapies that could revolutionize the treatment landscape for HCC.

Ulrich Steidl, M.D., Ph.D., professor and chair of cell biology at Albert Einstein College of Medicine and deputy director at the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center, has been elected a member of the Association of American Physicians (AAP), a prestigious 140-year-old honorary society dedicated to advancing medical knowledge through basic and clinical science.

Researchers at Karolinska Institutet have uncovered a unique ability of a special subtype of natural killer cells in the immune system, called adaptive NK cells, to remember ovarian tumours and effectively attack them. The discovery, published in Cancer Immunology Research, could pave the way for new, more powerful immunotherapies for difficult-to-treat cancers.